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Received July 26, 2010; accepted October 18, 2010AbstractHere we presented a 60-year-old Taiwanese man with advanced gastrointestinal stromal tumor. Disease progression was noted during
imatinib treatment. Surgical resection was done and mutation analysis of KIT gene in all the resected tumors revealed deletion mutations of
codons 558e565 in exon 11, whereas a missense mutation was also identified at codon 822 in exon 17 in one resected tumor. Patient’s disease
was refractory to escalating dose of imatinib and dasatinb. Surprisingly, combination of imatinib with pegylated liposomal doxorubicin produced
a substantial response and resulted in a 5-month progression free period for this imatinib-resistant gastrointestinal stromal tumor.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal neoplasms of the gastrointestinal tract,
resulting from mutations in c-kit and platelet derived growth
factor receptor.1 GISTs can arise anywhere along the gastro-
intestinal tract but are most common in the stomach (50%)
and small bowel (25%).2 The primary treatment is curative
surgery. When GIST became metastatic, it is generally
considered chemo-resistant.3 The most common metastatic
site are liver and peritoneum. Imatinib, which inhibits the
activated mutant c-kit and platelet derived growth factor
receptor, has become the first line treatment of advanced* Corresponding author. Dr. Ta-Chung Chao, Department of Medicine,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112,
Taiwan, ROC.
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doi:10.1016/j.jcma.2011.04.007GISTs.4e6 The initial standard dose 400 mg/day was consid-
ered to be safe and to achieve response induction. Dose
escalation to 80 mg/day is a reasonable option for patients
progressing on 400 mg/day.4e8 However, some patients posses
primary resistance and others may develop secondary resis-
tance after several months of imatinib treatment. We here
report a case with metastatic GIST developed secondary
resistance after imatinib treatment successfully treated with
combination of imatinib and pegylated liposomal doxorubicin
(PLD).
2. Case report
A 60-year-old Taiwanese man was diagnosed with an
advanced GIST in March of 2008 after several months of
abdominal fullness and poor appetite. A computed tomog-
raphy (CT) guided biopsy of the abdominal mass was per-
formed, and histopathological examination showed typicalhinese Medical Association. All rights reserved.
Fig. 1. Mutation analysis of all resected tumor showing codon 558e565 deletion in exon 11 in all resected tumor (A, arrow) and N mutation in exon 17 in one
resected tumor (B, arrow).
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Imatinib 400 mg per day was prescribed with good
response. However, a follow-up abdominal CT scan 7 months
after imatinib treatment showed progressive change and new
liver metastases. All recurrent tumors were resected in the
December of 2008. Mutation analysis of KIT gene in all the
resected tumors revealed deletion mutations of codons
558e565 in exon 11 (Fig. 1A), whereas a missense mutationFig. 2. Computed tomography scan showed the treatment response of the tumor bu
administration of Liposomal doxorubicin.was also identified at codon 822 in exon 17 in one resected
tumor (Fig. 1B). The daily imatinib dose was then increased to
800 mg. Unfortunately, abdominal CT scan, one month later,
showed tumor progression in the liver and peritoneal seeding.
Palliative surgery was performed, and imatinib was continued
at the same dose. However, generalized disease progression
over liver and peritoneum was found three months later
(Fig. 2A and B). Therapy was then changed to 400 mgrden before (A and B, arrow, April 2009) and after (C and D, arrow, Jun 2009)
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patient experienced increased ascites. Positron emission
tomography scan showed high uptake of flurodeoxyglucose 18
in the tumors. Dasatinib was discontinued, whereas imatinib
was maintained at 400 mg per day. Furthermore, PLD50 mg/
m2 every three weeks was administered as salvage chemo-
therapy. The ascites remarkably improved after one dose of
PLD administration. The follow-up abdominal CT scan 2
months later revealed a marked decrease of ascites and
shrinkage of the liver and peritoneal metastases (Fig. 2C and
D, indicated by the arrows). Unfortunately, a CT scan of the
abdomen five months later (after 7 doses of PLD) revealed
disease progression. Combination of imatinib and PLD
resulted in a 5-month progression free period for this patient
with imatinib-resistant GIST.
3. Discussion
Secondary resistance, which most often results from
secondary mutations of KIT exon 13 or 17, is almost inevitable
after imatinib treatment. For this case with exon 17 mutations,
there are few treatment options available.9 Surgical interven-
tion was performed for the first local recurrence, as recom-
mended by previous publications.10,11 Unfortunately, as
disease progressed, dasatinib was chosen based on its in vitro
efficacy only.12e14 However, it did not produce any response
and instead worsened patient’s condition. Previous studies
failed to show efficacy of PLD alone in treating advanced
GIST.15,16 However, in this particular case, combination of
PLD with imatinib produced a dramatic response by halting
the rapidly deteriorating disease course and inducing a sus-
tained tumor-control period. PLD may indeed show efficacy in
GIST when used in combination with imatinib. Furthermore,
the use of PLD may result in a higher intra-tumor concen-
tration of doxorubicin, which can overcome the chemotherapy
resistance. The response seen in this patient is significant and
provides evidence of clinical benefit of combining imatinib
and PLD in treating imatinib-resistant GIST. This combination
treatment warrants further study.
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